Novo Nordisk’s popular weight-loss drug, Wegovy, has been approved for sale in China, a significant victory for the Danish pharmaceutical giant. This green light unlocks the world’s second-largest economy, which is estimated to have the highest number of overweight or obese individuals globally. The approval news, announced in March 2024, comes at a crucial time for Novo Nordisk. China presents a massive potential market, but the company needs help. Wegovy is an injectable medication, and like other places, Novo Nordisk
